Description

With the sustained economic development and the improvements in diet, Chinese people’s blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the coming ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising. The annual market size of statin drug is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20% .

View Full Report at: http://www.marketresearchreports.biz/analysis/289127

Ezetimibe, the first cholesterol absorption selective inhibitor in the world, was jointly developed by Merck and Schering-Plough and approved by FDA in 2002 as the first drug for regulating blood fat with completely innovative mechanism of action after statin. Ezetimibe can selectively inhibit cholesterol transporter in the small intestine, effectively reduce cholesterol absorption, lower plasma cholesterol level and decrease the amount of cholesterol normally available to liver cells. As an ideal partner of statin, ezetimibe can provide better control rates for LDL-C with good safety and tolerance than doubled statin dose or more potent statin.

Ezetimibe in the Chinese market is monopolized by Schering-Plough. Ezetimibe develops fast after entering China with annual sales rising from less than CNY 0.05 million in 2007 to CNY 20.67 million in 2014 and CAGR during this period reaching up to 137%.

Ezetimibe enjoys a vast demand in China and its market size is expected to grow in the next few years.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/289127

Readers can get at least the following information from this report:

market size of ezetimibe in China
price of ezetimibe in Chinese market
market outlook of ezetimibe in China

The author suggests the following groups of people purchase this report:

manufacturers of lipid-lowering drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Content

1 Related Concepts of Ezetimibe
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Ezetimibe in China
2.1 Patent and Approval Status of Ezetimibe in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Ezetimibe in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz

Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]